Leprosy Treatment Market Size Worth $ 5,000.33 Million By 2032 | CAGR: 4.6%

Leprosy Treatment Market Size Worth $ 5,000.33 Million By 2032 | CAGR: 4.6%

The global Leprosy Treatment market size is expected to reach USD 5,000.33 million by 2032, according to a new study by Polaris Market Research. The report “Leprosy Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial, Leprostatics, Sulfone, Phenazine, Anti-tubercular Drugs, and Others); By Disease Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2023- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The demand for leprosy treatment is growing more quickly due to the increasing incidence of skin diseases. The prevalence of skin conditions like psoriasis and leprosy has increased in nations like China and India, which has fueled the market. According to the World Health Organization, around 120 countries have leprosy cases, and more than 200,000 cases are reported yearly. Hundreds of millions of people have skin NTDs.

Additionally, leprosy, an NTD, hurts the standard of living of mainly marginalized populations in remote rural areas and causes immense discomfort, suffering, stigmatization, and mental distress. The prevalence of high occurrences provides that some regions of the world experience both high incidence and high transmission rates. In the past 20 years, the WHO estimates that approximately 16 million leprosy cases have been treated. Therefore, the rising prevalence of skin disease and NTD prevalence has increased the demand for leprosy treatment, driving the market's growth over the forecast period.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/leprosy-treatment-market/request-for-sample

As per the WHO, the number of people needing interventions for NTDs has fallen by 25% over the past ten years, by about 80 million people between 2020 and 2021. Additionally, there is a consistent decline in the disease burden measured in years of life with a disability. Between 2016 and 2019, more than one billion individuals received treatment annually. By the end of 2022, 47 nations had eliminated at least one NTD. 

However, the COVID-19 pandemic severely affected NTD programs, which resulted in a decrease in the implementation of community-based interventions, a restriction on access to services provided by healthcare facilities, and negative effects on the supply chains for medical supplies, disrupting this promising trend. As a result, between 2019 and 2020, 34% fewer people were treated for NTDs.

Leprosy Treatment Market Report Highlights

  • The injectable route of administration segment is anticipated to grow at a significant CAGR over the forecast period owing to the drug of first preference for treating leprosy being dapsone.
  • Anti-tubercular drugs are expected to hold a significant market share over the forecast period due to drugs such as Rifampin treating both TB and leprosy.
  • Asia-Pacific is expected to grow at a considerable CAGR over the projected period on account of the rising disease prevalence as well as the government programs to support the treatment.
  • The global players include Astra Zeneca, Bayer, GSK, Johnson & Johnson, Merck, Pfizer Inc., Systopic Laboratories, Sanofi, and Teva Pharmaceutical.

Polaris Market Research has segmented the Leprosy Treatment market report based on drug class, route of administration, disease type, distribution channel, and region:

Leprosy Treatment, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

  • Antibacterial
  • Leprostatics
  • Sulfone
  • Phenazine
  • Anti-tubercular Drugs
  • Others

Leprosy Treatment, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Injectable
  • Topical

Leprosy Treatment, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Paucibacillary Leprosy
  • Multibacillary Leprosy

Leprosy Treatment, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Leprosy Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Leprosy Treatment Market Report Scope

Report Attributes


Market size value in 2023

USD 3,321.60 million

Revenue Forecast in 2032

USD 5,000.33 million


4.6% from 2022 - 2030

Base year


Historical data

2019 - 2021

Forecast period

2023 - 2032

Quantitative units

Revenue in USD million/billion and CAGR from 2023 to 2032

Segments Covered

By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key Companies

Acme Pharmaceuticals, Astra Zeneca Pharma India Ltd., Bayer AG, Bristol-Myers Squibb and Company, Cadila Pharmaceuticals Corp., Eli Lily and Company, Genetic Pharma, Glaxo Smithcline Pharmaceuticals Ltd., IDPL, Johnson & Johnson Services Inc., Lark Laboratories (India) Ltd., Merck & Co., Macleods Pharmaceuticals, Novartis International AG, Pfizer Inc., Systopic Laboratories Pvt. Ltd., Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

For Specific Research Requirements

Request for Customized Report